GOCM
ACAD icon

Green Owl Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Green Owl Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-20,000
Closed -$9K – 90
2015
Q2 		$9K Buy
+20,000
New +$774K 0.01% 81

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Green Owl Capital Management's ACAD Position: Q2 2016 in Review

Green Owl Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2016, closing a stake of 10,001 shares — an estimated $280K sold.

Green Owl Capital Management first reported a position in ACAD in Q2 2015 and held it in 3 quarters. The position peaked at $1.68M in Q2 2015. 227 funds tracked by Wall St. Rank hold ACAD as of Q2 2016.

  • Green Owl Capital Management reported no remaining Acadia Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Green Owl Capital Management sold 10,001 Acadia Pharmaceuticals shares in Q2 2016, an estimated $280K.
  • Green Owl Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2015 and held it in 3 quarters.
  • Green Owl Capital Management's Acadia Pharmaceuticals position peaked at $1.68M in Q2 2015.
  • 227 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2016.

Based on Green Owl Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.